Calcium antagonists and cancer: Causation or association

Cardiovascular Drugs and Therapy

Volumn 12, Issue 6, 1998, Pages 511-513

  Pahor, Marco ^a,b   Furberg, Curt D ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NIFEDIPINE; VERAPAMIL;

APOPTOSIS; BREAST CANCER; CANCER; CANCER GROWTH; CLINICAL TRIAL; COLON CANCER; DIABETES MELLITUS; DRUG SAFETY; EDITORIAL; HUMAN; HYPERTENSION; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

CALCIUM CHANNEL BLOCKERS; EPIDEMIOLOGIC METHODS; HUMANS; NEOPLASMS;

EID: 0032458563     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007706529684     Document Type: Editorial

References (25)

1. 1. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
2. 2. Pahor M, Guralnik JM, Corti C, Foley DJ, Carbonin PU, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43: 1191-1197.
3. 3. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
4. 4. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): A randomized controlled trial. JAMA 1996;276:785-791.
5. 5. Wagenknecht LE, Furberg CD, Hammon JW, Legault C, Troost BT. Surgical bleeding: Unexpected effect of a calcium antagonist. Br Med J 1995;310:776-777.
6. 6. Zuccala G, Pahor M, Landi F, et al. Use of calcium antagonists and need for perioperative transfusion in older patients with hip fracture: Observational study. Br Med J 1997;314:643-644.
7. 7. Pahor M, Guralnik JM, Furberg CD, Carbonin PU, Havlik RJ. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996;347:1061-1065.
8. 8. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695-699.
9. 9. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493-497.
10. 10. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium channel blockers and risk of cancer. Lancet 1997;349:525-528.
11. 11. Hardell L, Fredrikson M, Axelson O. Case-control study on colon cancer regarding previous diseases and drug intake. Int J Oncol 1996;8:439-444.
12. 12. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997;80:1439-1447.
13. 13. Daling JR. Calcium channel blockers and cancer: Is an association biologically plansible? Am J Hypertens 1996;9: 713-714.
14. 14. Li LH, Wine RN, Miller DS, Reece JM, Smith M, Chapin RE. Protection against methoxyacetic-acid-induced spermatocyte apoptosis with calcium channel blockers in cultured rat seminiferous tubules: Possible mechanisms. Toxicol Appl Pharmacol 1997;144:105-119.
15. 15. Correale P, Tagliaferri P, Celio L, Genua G, Montagnani S, Bianco AR. Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. Eur J Cancer 1991;27:1393-1395.
16. 16. Pahor M, Kritchevsky SB, Zuccala' G, Guralnik JM. Diabetes and risk of adverse events with calcium antagonists. Diabetes Care 1998;21:193-194.
17. 17. Braun S, Boyko V, Behar S, et al. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Benzafibrate Infarction Prevention (BIP) Study Research Group. J Am Coll Cardiol 1998;31:804-808.
18. 18. Hole DJ, Gillis CR, McCallum IR, et al. Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens 1998;16:119-124.
19. 19. Jonas M, Goldbourt U, Boyko V, Mandelzweig L, Behar S, Reicher-Reiss H. Nifedipine and cancer mortality: Ten-year follow-up of 2607 patients after acute myocardial infarction. Cardiovasc Drugs Ther 1998;12:177-181.
20. 20. Rosenberg L, Rao RS, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA 1998;279:1000-1004.
21. 21. Olsen JH, Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997;29: 1091-1094.
22. 22. The Israeli Sprint Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. The Israeli Sprint Study Group. Eur Heart J 1988;9:354-364.
23. 23. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352:179-184.
24. 24. Pahor M, Furberg CD. Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies. Drugs Aging 1998;13:99-108.
25. 25. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764.